Pyrotinib

Generic Name
Pyrotinib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C32H31ClN6O3
CAS Number
1269662-73-8
Unique Ingredient Identifier
CJN36EQM0H
Background

Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer

Conditions
Breast Cancer
First Posted Date
2021-09-01
Last Posted Date
2022-03-02
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
50
Registration Number
NCT05030519
Locations
🇨🇳

China, Zhejiang, Hangzhou, China

Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

Phase 3
Not yet recruiting
Conditions
Breast Cancer
Interventions
Drug: Pyrotinib
Drug: Trastuzumab
First Posted Date
2021-07-22
Last Posted Date
2021-07-22
Lead Sponsor
Shengjing Hospital
Target Recruit Count
450
Registration Number
NCT04973319
Locations
🇨🇳

Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

First Posted Date
2021-07-15
Last Posted Date
2021-07-15
Lead Sponsor
Zhiyong Yu
Target Recruit Count
100
Registration Number
NCT04963595

Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer

Conditions
Breast Cancer
Interventions
Drug: Pyrotinib
First Posted Date
2021-05-24
Last Posted Date
2021-05-24
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
100
Registration Number
NCT04899128
Locations
🇨🇳

Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China

Pyrotinib in Combination with Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: a Phase II Trial

First Posted Date
2021-05-05
Last Posted Date
2024-11-04
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
140
Registration Number
NCT04872985
Locations
🇨🇳

Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University, Guangzhou, Guangdong, China

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

Completed
Conditions
HER2-positive Breast Cancer
Interventions
Drug: Pyrotinib
First Posted Date
2021-02-16
Last Posted Date
2021-02-16
Lead Sponsor
Biyun Wang, MD
Target Recruit Count
30
Registration Number
NCT04756921
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

First Posted Date
2021-02-03
Last Posted Date
2021-02-03
Lead Sponsor
Peking Union Medical College
Target Recruit Count
270
Registration Number
NCT04736589
Locations
🇨🇳

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

First Posted Date
2021-01-22
Last Posted Date
2021-06-04
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
60
Registration Number
NCT04717531
Locations
🇨🇳

the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

First Posted Date
2020-12-24
Last Posted Date
2020-12-24
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
80
Registration Number
NCT04683445
Locations
🇨🇳

Sun Yat Sen Memorial Hospital，Sun Yat sen University, Guangzhou, Guangdong, China

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

First Posted Date
2020-12-23
Last Posted Date
2020-12-23
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
71
Registration Number
NCT04681911
Locations
🇨🇳

Sun Yat Sen Memorial Hospital，Sun Yat sen University, Guangzhou, Guangdong, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy